@article{oai:kanazawa-u.repo.nii.ac.jp:00026595,
 author = {Yoshizaki, Tomokazu and Wakisaka, Naohiro and Kondo, Satoru and Murono, Shigeyuki and Shimizu, Yoshinori and Nakashima, Masashi and Tsuji, Akira and Furukawa, Mitsuru},
 issue = {5},
 journal = {Journal of Medical Virology},
 month = {May},
 note = {Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated malignant tumor. Recently, cidofovir, an anti-viral drug which is an acyclic nucleoside analogue, has been reported to have an anti-tumor potential. Two patients with NPC, who had previously received multi-round therapy, were treated with cidofovir. Cidofovir was topically injected in and around the tumor once every 3 weeks (originally 75 mg/ml sulution, diluted to 15 mg/ml just before injection, 37.5 mg of cidofoviratatime).Tumorgrowth was suppressed for several months around the injection site in each patient. EBV-encoded RNAs in situ hybridization revealed the reduction of the tumor cell population; however, the EBER expression was still maintained in the NPC tumor cells. Although the anti-tumor mechanism remains unclear, these results suggest that cidofovir is actually an effective and safe agent for the treatment of NPC. © 2008 Wiley-Liss, Inc., 金沢大学附属病院耳鼻咽喉科},
 pages = {879--882},
 title = {Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir},
 volume = {80},
 year = {2008}
}